Everything below concerns GHRH receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-24. Numbers and descriptions here follow the published literature rather than marketing material.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
=== Europe === Marketing authorisation for 177Lu-DOTATATE was granted by the European Medicines Agency on 26 September 2017. 90Y-DOTATOC (international nonproprietary name: yttrium (90Y) edotreotide) and 177Lu-DOTATOC are designated as orphan drugs, but have not yet received marketing authorisation.
Geographic data related to Portugal at OpenStreetMap National English language newspaper National Wine Website News about Portugal from the Portuguese American Journal Portugal at UCB Libraries GovPubs Portugal profile from the BBC News Prestage, Edgar; Jayne, Kingsley Garland (1911). "Portugal" . Encyclopædia Britannica. Vol. 22 (11th ed.). p. 134–163. Portuguese Pamphlets Collection from the Rare Book and Special Collections Division at the Library of Congress Wikimedia Atlas of Portugal Government Official Parliament website Official Portuguese Government website (in English and Portuguese) Trade World Bank Summary Trade Statistics Portugal Travel Official Portuguese Government Travel/media website Official Travel and Tourism office website
=== Fruit === The fruit is generally a wind-dispersed capsule, but occasionally a berry (Medeoleae) which is dispersed by animals. A capsule that is usually loculicidal (splitting along the locules) as in the Lilioideae, but occasionally septicidal (splitting between them, along the separating septa) in the Calachortoideae and wind dispersed, although the Medeoleae form berries (baccate). The seeds may be flat, oblong, angular, discoid, ellipsoid or globose (spherical), or compressed with a well developed epidermis. The exterior may be smooth or roughened, with a wing or raphe (ridge), aril or one to two tails, rarely hairy, but may be dull or shiny and the lack of a black integument distinguishes them from related taxa such as Allioideae that were previously included in this family, and striate (parallel longitudinally ridged) in the Steptopoideae. The hilum (scar) is generally inconspicuous. The bitegmic (separate testa and tegmen) seed coat itself may be thin, suberose (like cork), or crustaceous (hard or brittle). The endosperm is abundant, cartilaginous (fleshy) or horny and contains oils and aleurone but not starch (non-farinaceous). Its cells are polyploid (triploid or pentaploid, depending on the embryo sac type). The embryo is small (usually less than one quarter of seed volume), axile (radially sectioned), linear (longer than broad) or rarely rudimentary (tiny relative to endosperm) depending on placentation type, and straight, bent, curved or curled at the upper end.
Sources: en.wikipedia.org
In human adult females, the primordial follicle is composed of a single oocyte surrounded by a layer of closely associated granulosa cells. In early stages of the ovarian cycle, the developing follicle acquires a layer of connective tissue and associated blood vessels. This covering is called the theca. As development of the secondary follicle progresses, granulosa cells proliferate to form the multilayered membrana granulosum. Over a period of months, the granulosa cells and thecal cells secrete follicular fluid (a mixture of hormones, enzymes, and anticoagulants) to nourish the maturing ovum. In tertiary follicles, the single-layered theca differentiates into a theca interna and theca externa. The theca interna contains glandular cells and many small blood vessels, while the theca externa is composed of dense connective tissue and larger blood vessels.
It allows for the highest levels of exercise intensity, but intramuscular stores of phosphocreatine are very limited and can only provide energy for exercises lasting up to ten seconds. Recovery is very quick, with full creatine stores regenerated within five minutes.
== Presentations and papers == "Left 4 Dead" - Game Audio Network Guild Summer Summit (2010) "Matrix Revolutions: Techniques and Methodologies With Large Scale Sentinel 'Swarm' Scenes" - Silicon Valley ACM Siggraph (2004) "Matrix Sequels: Animation and Pipeline Methodologies in Large CG Film Productions" - San Francisco ACM Siggraph Student Chapter (2004) "Wiring Cracker: The Mechanics of a Non-Anthropomorphic, Real-Time, Performance Animation Puppet" - ACM Siggraph (1998)
Sources: en.wikipedia.org
5-Hydroxyeicosanoid dehydrogenase (5-HEDH) or more formally, nicotinamide adenine dinucleotide phosphate (NADP+)-dependent dehydrogenase, is an enzyme that metabolizes between two eicosanoid metabolites of arachidonate 5-lipoxygenase (5-LOX): 5-hydroxyeicosatetraenoic acid (5-(S)-HETE), and its 5-keto analog 5-oxo-eicosatetraenoic acid (5-oxo-ETE). It also acts in the reverse direction, metabolizing 5-oxo-ETE to 5(S)-HETE. Since 5-oxo-ETE is 30–100-fold more potent than 5(S)-HETE in stimulating various cell types, 5-HEDH is regarded as a regulator and promoter of the influence that 5-LOX and its metabolites have on cell function. Although 5-HEDH has been evaluated in a wide range of intact cells and in crude microsome preparations, it has not yet been evaluated for its structure or gene, and most studies on it have been limited to human tissues.
US Health Physics Society United Nations "Human rights and weapons of mass destruction, or with indiscriminate effect, or of a nature to cause superfluous injury or unnecessary suffering" (The UN 2002 report) Depleted Uranium and the IAEA Scientific reports ATSDR – Case Studies in Environmental Medicine (CSEM): Uranium Toxicity Archived 4 February 2016 at the Wayback Machine U.S. Department of Health and Human Services "Depleted Uranium in Bosnia and Herzegovina – Postconflict Assessment" Archived 25 February 2012 at the Wayback Machine by UN Environment Programme "Radiological Conditions in Areas of Kuwait With Residues of Depleted Uranium" by International Atomic Energy Agency "Technical Report on Capacity-building for the Assessment of Depleted Uranium in Iraq" Archived 9 March 2012 at the Wayback Machine by UN Environment Programme "A Review of the Scientific Literature As It Pertains to Gulf War Illnesses" by RAND Depleted Uranium article from the Royal Society (archived) An Analysis of Uranium Dispersal and Health Effects Using a Gulf War Case Study by Sandia National Laboratories Depleted Uranium Human Health Fact Sheet by Argonne National Laboratory Environmental Assessment Division Depleted uranium (DU) normative value pilot study: levels of uranium in urine samples from the general population Archived 26 July 2011 at the Wayback Machine by A.D. Jones, B. G. Miller, S. Walker, J. Anderson, A. P. Colvin, P.A. Hutchison, C.A. Soutar.
{\displaystyle {\frac {D{\boldsymbol {\omega }}}{Dt}}={\frac {\partial {\boldsymbol {\omega }}}{\partial t}}+(\mathbf {u} \cdot \nabla ){\boldsymbol {\omega }}=({\boldsymbol {\omega }}\cdot \nabla )\mathbf {u} }
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.